Literature DB >> 28868261

Nonalcoholic Fatty Liver Disease Is Not Associated with Thyroid Hormone Levels and Hypothyroidism: A Systematic Review and Meta-Analysis.

Veeravich Jaruvongvanich1,2, Anawin Sanguankeo3,4, Sikarin Upala3,4.   

Abstract

BACKGROUND: Whether hypothyroidism is related to nonalcoholic fatty liver disease (NAFLD) is unclear. Thyroid dysfunction is closely related with components of metabolic syndrome. Given the hepatic manifestation of metabolic syndrome, several studies have investigated the association between NAFLD and thyroid dysfunction and have demonstrated inconsistent results. Thus, we conducted a systematic review and meta-analysis to better characterize the association between NAFLD and thyroid dysfunction.
METHODS: MEDLINE and Embase were searched through July 2016. The primary outcome was the association between NAFLD and subclinical, overt, and overall hypothyroidism. The secondary outcome was the difference in thyroid hormone levels (free triiodothyronine [FT3], free thyroxine [FT4], or thyroid-stimulating hormone [TSH]) between NAFLD patients and non-NAFLD controls. Pooled odds ratios (OR) and 95% CI were calculated using a random-effects model. All continuous data are summarized as the mean difference along with 95% CI.
RESULTS: Data were extracted from 14 studies involving 7,191 NAFLD patients and 30,003 controls. NAFLD was not associated with subclinical, overt, or overall hypothyroidism compared with non-NAFLD controls. Patients who had NAFLD did not show a significant difference in FT3, FT4, or TSH compared with non-NAFLD controls.
CONCLUSIONS: Our meta-analysis demonstrates no significant association between NAFLD and subclinical, overt, or overall hypothyroidism, and we also found no significant difference in thyroid hormone levels between participants with and without NAFLD.

Entities:  

Keywords:  Hypothyroidism; Meta-analysis; Nonalcoholic fatty liver disease; Thyroid function

Year:  2017        PMID: 28868261      PMCID: PMC5567115          DOI: 10.1159/000454920

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  33 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India.

Authors:  Pathik Parikh; Aniruddha Phadke; Prabha Sawant
Journal:  Indian J Gastroenterol       Date:  2015-04-16

3.  Non-alcoholic fatty liver disease across the spectrum of hypothyroidism.

Authors:  Goh Eun Chung; Donghee Kim; Won Kim; Jeong Yoon Yim; Min Jung Park; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  J Hepatol       Date:  2012-03-14       Impact factor: 25.083

4.  Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects.

Authors:  Yang Tao; Hongbing Gu; Jingcheng Wu; Jian Sui
Journal:  Endocr Res       Date:  2014-10-20       Impact factor: 1.720

5.  Metabolic syndrome prevalence in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters.

Authors:  M Erdogan; A Canataroglu; S Ganidagli; M Kulaksızoglu
Journal:  J Endocrinol Invest       Date:  2010-07-22       Impact factor: 4.256

Review 6.  Radiologic evaluation of nonalcoholic fatty liver disease.

Authors:  Seung Soo Lee; Seong Ho Park
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study.

Authors:  Kil Woo Lee; Ki Bae Bang; Eun Jung Rhee; Heon Ju Kwon; Mi Yeon Lee; Yong Kyun Cho
Journal:  Clin Mol Hepatol       Date:  2015-12-24

Review 8.  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Stergios A Polyzos; Konstantinos N Aronis; Jannis Kountouras; Dimitrios D Raptis; Maria F Vasiloglou; Christos S Mantzoros
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

9.  Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile.

Authors:  Yenna Lee; Young Joo Park; Hwa Young Ahn; Jung Ah Lim; Kyoung Un Park; Sung Hee Choi; Do Joon Park; Byung-Chul Oh; Hak C Jang; Ka Hee Yi
Journal:  Endocr J       Date:  2013-06-12       Impact factor: 2.349

10.  Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania.

Authors:  Till Ittermann; Robin Haring; Henri Wallaschofski; Sebastian E Baumeister; Matthias Nauck; Marcus Dörr; Markus M Lerch; Markus Lerch; Henriette E Meyer zu Schwabedissen; Dieter Rosskopf; Henry Völzke
Journal:  Thyroid       Date:  2012-05-10       Impact factor: 6.568

View more
  23 in total

1.  Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis.

Authors:  Paul Manka; Lars Bechmann; Jan Best; Svenja Sydor; Lee C Claridge; Jason D Coombes; Ali Canbay; Lars Moeller; Guido Gerken; Heiner Wedemeyer; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2019-06-03       Impact factor: 3.199

2.  Thyroid Dysfunction and Nonalcoholic Fatty Liver Disease: We Need New Larger and Well-Designed Longitudinal Studies.

Authors:  Alessandro Mantovani; Giorgio Grani
Journal:  Dig Dis Sci       Date:  2018-04-19       Impact factor: 3.199

3.  Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015.

Authors:  Jeongmin Lee; Jeonghoon Ha; Kwanhoon Jo; Dong-Jun Lim; Jung-Min Lee; Sang-Ah Chang; Moo-Il Kang; Bong-Yun Cha; Min-Hee Kim
Journal:  Sci Rep       Date:  2018-10-11       Impact factor: 4.379

Review 4.  Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options.

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Ecaterina Neculae; Claudia Florida Costea; Manuela Ciocoiu; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Mariana Floria
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

5.  Hypothyroidism and related diseases: a methodological quality assessment of meta-analysis.

Authors:  Limin Tian; Feifei Shao; Yahong Qin; Qian Guo; Cuixia Gao
Journal:  BMJ Open       Date:  2019-03-30       Impact factor: 2.692

6.  Thyroid-stimulating hormone is associated with nonalcoholic steatohepatitis in patients with chronic hepatitis B.

Authors:  Liang Liu; Ping Li; Yuqiang Mi; Yonggang Liu; Yiqi Liu; Peng Zhang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

7.  Association between TSH levels within the reference range and adiposity markers at the baseline of the ELSA-Brasil study.

Authors:  Maria de Fátima Haueisen Sander Diniz; Alline Maria Rezende Beleigoli; Isabela M Benseñor; Paulo A Lotufo; Alessandra C Goulart; Sandhi Maria Barreto
Journal:  PLoS One       Date:  2020-02-07       Impact factor: 3.240

Review 8.  Hepatocrinology.

Authors:  Sanjay Kalra; Saptarshi Bhattacharya; Pawan Rawal
Journal:  Med Sci (Basel)       Date:  2021-06-01

9.  Thyroid-stimulating hormone is an independent risk factor of non-alcoholic fatty liver disease.

Authors:  Kazuki Tahara; Takemi Akahane; Tadashi Namisaki; Kei Moriya; Hideto Kawaratani; Kosuke Kaji; Hiroaki Takaya; Yasuhiko Sawada; Naotaka Shimozato; Shinya Sato; Soichiro Saikawa; Keisuke Nakanishi; Takuya Kubo; Yukihisa Fujinaga; Masanori Furukawa; Koh Kitagawa; Takahiro Ozutsumi; Yuuki Tsuji; Daisuke Kaya; Hiroyuki Ogawa; Hirotetsu Takagi; Koji Ishida; Akira Mitoro; Hitoshi Yoshiji
Journal:  JGH Open       Date:  2019-10-01

10.  Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity.

Authors:  Marta Borges-Canha; João Sérgio Neves; Fernando Mendonça; Maria Manuel Silva; Cláudia Costa; Pedro M Cabral; Vanessa Guerreiro; Rita Lourenço; Patrícia Meira; Daniela Salazar; Maria João Ferreira; Jorge Pedro; Ana Leite; Madalena Von-Hafe; Catarina Vale; Sara Viana; Ana Sande; Sandra Belo; Eva Lau; Paula Freitas; Davide Carvalho
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.